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Abstract
Background: Matrix metalloproteinases (MMP) -8 and -9 may play key roles in the modulation of neutrophilic lung
inflammation seen in pediatric Acute Respiratory Distress Syndrome (ARDS). We aimed to perform a comprehensive analysis
of MMP-8 and MMP-9 activity in tracheal aspirates of pediatric ARDS patients compared with non-ARDS controls, testing
whether increased MMP-8 and -9 activities were associated with clinical outcomes.
Methods: Tracheal aspirates were collected from 33 pediatric ARDS patients and 21 non-ARDS controls at 48 hours of
intubation, and serially for those who remained intubated greater than five days. MMPs, tissue inhibitor of
metalloproteinases (TIMPs), human neutrophil elastase (HNE) and myeloperoxidase (MPO) activity were measured by
ELISA, and correlated with clinical indicators of disease severity such as PRISM (Pediatric Risk of Mortality) scores, oxygen
index (OI), multi-organ system failure (MOSF) and clinical outcome measures including length of intubation, ventilator-free
days (VFDs) and mortality in the Pediatric Intensive Care Unit (PICU).
Results: Active MMP-9 was elevated early in pediatric ARDS subjects compared to non-ARDS controls. Higher MMP-8 and
active MMP-9 levels at 48 hours correlated with a longer course of mechanical ventilation (r=0.41, p=0.018 and r=0.75,
p,0.001; respectively) and fewer number of VFDs (r=20.43, p=0.013 and r=20.76, p,0.001; respectively), independent
of age, gender and severity of illness. Patients with the highest number of ventilator days had the highest levels of active
MMP-9. MMP-9 and to a lesser extent MMP-8 activities in tracheal aspirates from ARDS subjects were sensitive to blockade
by small molecule inhibitors.
Conclusions: Higher MMP-8 and active MMP-9 levels at 48 hours of disease onset are associated with a longer duration
of mechanical ventilation and fewer ventilator-free days among pediatric patients with ARDS. Together, these results
identify early biomarkers predictive of disease course and potential therapeutic targets for this life threatening
disease.
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Introduction
Acute Lung Injury (ALI), and in its most severe form, Acute
Respiratory Distress Syndrome (ARDS) is a common, life-
threatening cause of respiratory failure in children. Recent
studies support a role for neutrophil-derived MMP-8 and -9, and
an imbalance with their natural inhibitors, TIMPs in the
pathogenesis of adult ALI and ARDS [1–5]. Despite our
increasing understanding of the biologic activities of MMP-8
and-9, the role of these MMPs in pediatric ALI and ARDS
remains ill defined. Examination of MMP activity in pediatric
ARDS is important and potentially different than what has been
described in adult ARDS for a number of reasons, including
different etiologies underlying pediatric ARDS compared with
adults, significant differences in immune function, and the
potential for greater tissue plasticity during recovery from
pediatric disease [6]. We previously identified high levels of
MMP-8 and -9 relative to other MMPs in pooled lung secretions
of children with ALI [7]. In this present study, we extend our
previous observations by testing the hypothesis that MMP-8 and -
9 are dysregulated early in the disease and have prognostic value
in children with ARDS.
Materials and Methods
Ethic statement
This study was performed in the PICU at The Children’s
Hospital of Alabama with approval from the Institutional Review
Board at the University of Alabama at Birmingham and written
informed consent provided by legal guardians of the subject.
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ARDS subjects were children (#17 years of age) who required
mechanical ventilation and met clinical criteria for ARDS,
including hypoxemia as defined by partial pressure of oxygen in
arterial blood (PaO2)/fraction of oxygen in inspired air (FiO2)
#200 mm Hg, bilateral infiltrates on chest radiograph and no
clinical evidence of left atrial hypertension [8]. Patients were
excluded if they had recent use of immunosuppresion including
steroids or cytotoxic therapy. Control subjects were children (#17
years of age) who required mechanical ventilation for non-
pulmonary reasons, such as airway protection for head trauma or
status epilepticus. All controls had no evidence of acute or chronic
lung disease, with clear chest radiographs and minimal ventilatory
requirement {low FiO2-ranging from 0.25-0.35, positive end
expiratory pressure (PEEP) and ventilatory rate}. All radiographic
interpretations were confirmed by independent readings from
pediatric radiologists who were blinded to the study. Tracheal
aspirates from study subjects were collected via endotracheal tube
suctioning (with an 8F suction cannula, inserted past the
endotracheal tube) within 48 hours of intubation.
Data collection
Clinical data collected included patient demographics, diagnosis
associated with the onset of ARDS, radiographic findings, arterial
blood gases, OI, PaO2/FiO2 ratios, blood and tracheal aspirate
culture data, PRISM scores, MOSF [9] and duration of
mechanical ventilation. Number of ventilator-free days was
defined as the number of days after the onset of ARDS per 28
day month [10] or intubation (for control subjects) that the patient
was alive and not mechanically ventilated. During clinical data
collection, the responsible research coordinator was blinded to all
MMP and other biomarker data.
Endotracheal aspirate processing
Endotracheal tube aspirates were collected on ice and
centrifuged at 1000 RPM for 10 minutes, with separation of
pellet from supernatant. Once the supernatant was collected,
protein concentration was measured (Catalog # 5000112; Bio-
Rad), and then separate aliquots were saved at 4uC for
quantitative analysis of MMP-8, MMP-9, TIMP-1, MPO and
HNE.
Zymography
Zymography was performed on tracheal aspirates using a
modified technique [11] to measure total gelatinase activity. In
brief, samples (10 ug protein/sample) were subjected to electro-
phoresis through 7.5% polyacrylamide gels containing 1 mg/ml
porcine skin gelatin in the presence of SDS under non-reducing
conditions. Subsequently, gels were washed in 2.5% Triton X-100
for 1 hour at 4uC, then incubated in 50 mM TRIS and 5 mM
CaCl for 16 hours at 37uC. Finally, gels were stained for 30
minutes in Coomassie blue and destained for 1–2 hours. MMP-9
activity present in samples was visible as lytic areas within the
substrate gels.
Measurement of active and total MMP-9 concentrations
MMP-9 activity was quantified using a fluorometric assay (R&D
Systems # F9M00). 1 mM of Aminophenylmercuric acetate
(APMA), a chemical activator of MMP-9 was added to selected
samples to determine the total concentration of MMP-9 present,
including pro-MMP-9. Complementary samples without the
addition of APMA measured the amount of endogenously active
MMP-9 present in the samples.
Measurement of total MMP-8, TIMP-1, MPO and HNE
concentrations
MMP-8, TIMP-1(R&D Systems # DMP800 and DTM100;
respectively), MPO and HNE concentrations (Calbiochem #
475919 and CBA016; respectively) were measured using sandwich
enzyme immunoassay techniques. MMP-8 activity was not
routinely measured due to variable availability of standardized
MMP-8 activity ELISA kits.
Treatment of ARDS lower airway samples with MMP-8
and -9 inhibitors
Tracheal aspirates from ARDS subjects with high MMP-8 and -
9 activity were incubated with EDTA (5 mM), MMP-8 specific
inhibitor (Calbiochem #44237 at 30 ng/ml), MMP-9 specific
inhibitor (Calbiochem #444278 at 50 ng/ml) and doxycyline
(100 mcg/ml) or vehicle (DMSO, 1:1000) for 2 hours followed by
MMP-8 and -9 activity measurement (R&D Systems).
Statistical analysis
Descriptive statistics were computed for each study variable
of interest, including means, medians, standard error of the
means (SEM), and ranges. Since the distributions of the data
from the tracheal aspirate inflammatory markers deviated from
a normal distribution, these data were logarithmically trans-
f o r m e du s i n gal o g 10 scale prior to statistical analysis. The log-
transformed variables were determined to follow a normal
distribution through the use of the Kolmogorov-Smirnov test
and normal probability plots. Demographic and diagnostic
comparisons between ARDS and control subjects were
performed using the unpaired t-test for quantitative variables
and the two-group chi-square test (or Fisher’s exact test as
needed) for categorical variables. Overall comparisons between
ARDS and control subjects were performed using the unpaired
t-test, while comparisons including covariates of interest (two
disease etiologies, three disease s e v e r i t i e s ,a g e ,a n dg e n d e r )w e r e
performed using analysis of covariance. Comparisons between
48 hour and Day 6 measurements of total MMP-8, MMP-9 and
active MMP-9 were performed using the paired t-test. Pearson
correlation analysis was used to determine correlations between
pairs of quantitative variables and Spearman correlation
analysis was used to determine correlations between categorical
variables (MOSF and gender) and quantitative variables.
Simple and multiple linear regression analyses were used to
assess the ability of the markers (active MMP-9, total MMP-9,
percent active MMP-9, MMP-8, TIMP-1, MMP-9: TIMP-1,
HNE, and MPO) to predict the outcome measures (days of
intubation and ventilator-free days). Covariates included in the
multiple regression analyses were age, gender, disease etiolo-
gies, P/F ratio, OI index, PRISM scores and MOSF. One-way
analysis of variance was used to perform comparisons between
t h ef o u rq u a r t i l e sf o rA R D Ss u b j e c t s .T h eT u k e y - K r a m e r
multiple comparisons test was then used to determine which
specific pairs of means were significantly different. Where
possible, nonparametric statistical analyses (including the
Wilcoxon rank-sum test, the Wilcoxon signed rank test, the
Kruskal-Wallis test, and Spearman correlation analyses)
corresponding to the above analyses were performed, and
these analyses yielded results that are similar to those obtained
by the parametric analyses described above. Statistical tests
were two-sided and were performed using a 5% significance
level (i.e. alpha =0.05). Statistical analyses were performed
with the use of SAS software (version 9.2; SAS Institute, Inc.,
Cary, NC).
High MMP-8/9 Predicts Duration of Ventilation
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e22596Results
A summary of demographic and diagnostic information
regarding the pediatric ARDS and control subjects is shown in
Table 1. 21 control subjects and 33 patients who met criteria for
ARDS were enrolled prospectively over a two year period. In
comparison to control subjects, ARDS patients had worse overall
morbidity as indicated by longer duration of mechanical
ventilation, fewer number of VFDs and higher PRISM scores on
admission to the PICU (Table 1). At 48 hours of intubation and
ARDS onset, the mean PaO2/FiO2 ratios and OI in the ARDS
subjects was 153612 and 1865, respectively. ARDS was caused
by a pulmonary etiology in 82% of all cases and 78% with a
primary pulmonary process had an infectious etiology. Viral
pneumonia, defined by a positive rapid viral screen or viral culture
was seen in 41% {influenza (n=5), adenovirus (n=2), parainfluenza
(n=2) and respiratory syncytial virus (n=2)}, while bacterial
pneumonia, defined by a positive tracheal aspirate culture, was
seen in 30% {staphylococcus aureus (n=4), pseudomonas aeruginosa
(n=2), haemophilus non-influenza (1) and streptococcus pneumoniae (1)} of
this cohort. None of the control subjects had a positive tracheal
aspirate culture (viral or bacterial pathogens). Thirty-six percent of
ARDS subjects had multi-organ failure and one succumbed to the
disease. There were no fatalities in the control group, and none
had multi-organ failure.
MMP-9, MMP-8, MPO and HNE profile in early ARDS
Tracheal aspirates from ARDS subjects were initially probed for
MMP-9 activity by zymography. Figure 1A is an example of
robust gelatinase activity found in ARDS subjects at 48 hours of
intubation and ARDS diagnosis. In contrast, only sporadic lytic
activity was seen in control subjects (not shown). Using ELISA
techniques, the concentrations of endogenously active MMP-9 (i.e.
prior to APMA stimulation) in tracheal aspirates from patients
with ARDS were nearly 16-fold higher than controls (ARDS
mean6SEM=22.4610 ng/mg vs. controls=1.460.4 ng/mg;
p=0.001). Figure 1B demonstrates the range of this data, with
the highest and lowest values, and median data for both the ARDS
and control group. Using multivariate analysis to adjust for
differences in disease etiology (pulmonary versus non-pulmonary,
infectious versus non-infectious) and disease severity (PRISM
scores and MOSF) between ARDS and non-ARDS subjects, up-
regulation of active MMP-9 seen in the ARDS cohort remained
statistically significant (p=0.002). Comparison of total MMP-9
concentrations (includes both basal activity and inducible pro-
enzyme) between the ARDS subjects and controls also demon-
strated statistically significant differences between the groups
(measured after APMA stimulation to assess pro-MMP-9 con-
centrations; ARDS mean6SEM=184636 ng/mg vs. con-
trols=95626 ng/mg; p=0.009). Likewise, total MMP-8 concen-
trations were higher in the ARDS subjects compared to non-
ARDS controls (ARDS mean6SEM=9516242 ng/mg vs. con-
trol=384697 ng/mg; p=0.043). However, no differences were
observed for total MMP-8 and -9 concentrations between ARDS
and control subjects after adjusting for disease etiology and
severity of illness.
As surrogates of pulmonary neutrophil influx, MPO and HNE
concentrations in tracheal aspirates were measured in all subjects.
MPOlevelsfrom ARDS patientswerefound tobe approximately 7-
fold higher than in controls (MPO in ARDS mean6SEM=
926261696 ng/mg vs. control=13966439 ng/mg; p,0.001;
Figure 1C) which was confirmed by analysis of covariance (p=
0.004). For HNE levels, differences were present between ARDS
and control subjects (HNE in ARDS mean6SEM=12.564
ng/mg vs. control=4.461.1 ng/mg; p=0.25; Figure 1D) but did
not meet statistical significance by univariate and multivariate
Table 1. Demographic and diagnostic information of ARDS and control subjects.
Control ARDS P
Number 21 33
Age: Mean ± SEM
(Range)
6.561.4
(4 weeks - 17 years)
6.661.1
(6 weeks - 17 years)
0.95
Gender: F:M 6:15 14:19 0.30
Length of intubation
Mean days ± SEM (Range)
4.360.6 (1 day - 10 days) 1161.3 (4 days – 33 days) ,0.001
Ventilator-Free Days
Mean days ± SEM (Range)
23.760.6
(18 days – 27 days)
17.261.2
(0 days – 24 days)
,0.001
*PRISM 12 (Mean ± SEM) 7.761.6 12.561.2 0.018
PRISM 24 (Mean ± SEM) 5.761.2 10.260.8 0.003
{MOSF 0 13 (39%) ,0.001
Death 0 1 (3%) 1.0
Infectious 0 20 (61%) ,0.001
Pulmonary 0 27 (82%) ,0.001
Diagnosis Closed head injury (9)
Seizure (3)
Post laryngotracheal
reconstruction (3)
{Others (6)
Bacterial pneumonia (8)
Viral pneumonia (11)
Aspiration (2)
Pulmonary hemorrhage (2)
Sepsis (6)
Candidal pneumonia (1)
Eosinophilic pneumonia (1)
Smoke inhalation (1)
Pulmonary contusion (1)
*Pediatric Risk of Mortality;
{ Multi-organ System Failure;
{ventricular shunt failure, post spinal fusion, choking, arrhythmia, spinal muscular atrophy, esophagitis.
doi:10.1371/journal.pone.0022596.t001
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(Table 2; r=0.63; p,0.001) and both MMP-8 and MMP-9 levels
demonstrated positive correlations with MPO and HNE concen-
trations (Table 2), consistent with common sources for these
enzymes. The correlations ranged from moderate (MMP-9 with
HNE and MPO, MMP-8 with HNE and MPO) to low (MMP-8
and MMP-9).
TIMP-1 and MMP-9:TIMP-1 activity ratios in ARDS
TIMP-1 concentrations were slightly lower in the ARDS
subjects compared to controls (mean6SEM=113615 ng/mg
vs.144627 ng/mg, respectively; p=0.43), contributing to higher
MMP-9:TIMP-1 activity ratios in ARDS subjects compared to
controls (mean6SEM=2.760.6 vs. 1.460.5, respectively;
p=0.039).
Higher active MMP-9, fraction of active MMP-9 and total
MMP-8 levels at 48 hours predicts longer ARDS-related
ventilator support
At 48 hours of intubation and ARDS onset, increasing active
MMP-9 levels and fraction of active MMP-9 (active MMP-9/total
MMP-9) had strong positive correlation (r=0.75; p,0.001 and
0.61; p,0.001, respectively) with the need for prolonged
mechanical ventilation in the ARDS subjects. Similarly, higher
total MMP-8 levels at 48 hours of intubation correlated with
subjects who had longer ARDS-related ventilator support
(r=0.41; p=0.018). ARDS patients with higher active MMP-9
and fraction of active MMP-9 at 48 hours of disease onset also had
lower number of VFDs (r=20.76; p,0.001 and 20.60; p,0.001,
respectively). ARDS subjects with higher total MMP-8 concen-
trations at 48 hours also had lower number of VFDs (r=20.43;
p=0.013). Multiple regression analyses confirmed the observation
that higher levels of active MMP-9, percent active MMP-9 and
total MMP-8 at 48 hours of ARDS onset predicted the duration of
mechanical ventilation (p,0.001, p=0.005 and p=0.004; respec-
tively), after adjusting for disease etiology (pulmonary vs. non-
pulmonary, infectious vs. non-infectious), disease severity (ex:
PRISM scores, presence of MOSF), oxygenation defect (ex: P/F
ratios, OI), age and gender. Similarly, multiple regression analyses
demonstrated that higher active MMP-9, percent active MMP-9
and total MMP-8 correlated with fewer number of VFDs in the
ARDS subjects (p,0.001, p=0.004 and p=0.004; respectively).
No significant correlations were identified between total MMP-
9, TIMP-1, MMP-9:TIMP-1 ratios, HNE or MPO with duration
Figure 1. MMP-9, MPO and HNE levels in early pediatric ARDS. A. Zymogram (7.5% SDS non-reduced gel) demonstrates robust gelatinase
activity in tracheal aspirates from ARDS subjects. Each lane represents a sample obtained from separate ARDS subjects at 48 hours of disease onset
and intubation. The higher molecular weight band at 135 kDa (black arrow) likely represents lipocalin:MMP-9 complexes, while the 82 KDa band
(white arrow) corresponds with active MMP-9 isoforms. B. Endogenously active MMP-9 levels measured in tracheal aspirates of ARDS subjects at
48 hours of disease onset and intubation were elevated (16-fold) compared with control subjects (*p=0.001). Boxes represent 25
th to 75
th percentile
range, with the midline indicating the median; bars represent the highest and lowest values. C. MPO concentrations were elevated (7-fold) in ARDS
subjects compared to controls at 48 hours of intubation (*p,0.001). Boxes represent 25
th to 75
th percentile range, with the midline indicating the
median; bars represent the highest and lowest values. D. HNE concentrations were elevated (3-fold) in ARDS subjects compared to controls at
48 hours of intubation (*p=0.25). Boxes represent 25
th to 75
th percentile range, with the midline indicating the median; bars represent the highest
and lowest values.
doi:10.1371/journal.pone.0022596.g001
Table 2. Correlation coefficients for tracheal aspirate
inflammatory markers at 48 hours of ARDS.
rP
HNE and MPO 0.63 ,0.001
Total MMP-9 and HNE 0.47 0.006
Total MMP-9 and MPO 0.46 0.007
MMP-8 and HNE 0.56 ,0.001
MMP-8 and MPO 0.67 ,0.001
Total MMP-8 and MMP-9 0.38 0.031
Note: All correlations are indicative of positive relationships between these pairs
of variables.
doi:10.1371/journal.pone.0022596.t002
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Similarly, no clear relationship was observed between the
measured biomarkers and clinical indicators of disease severity
(P/F ratios, OI, PRISM 12, PRISM 24 and MOSF). In the control
non-ARDS group, no correlation was observed between the
tracheal aspirate biomarkers (active MMP-9, total MMP-9,
percent active MMP-9, MMP-8, TIMP-1, MMP-9:TIMP-1,
HNE and MPO) and clinical markers of disease severity and
outcome measures (P/F ratios, OI, PRISM 12, PRISM 24,
MOSF, duration of intubation and VFDs).
To further examine relationships between duration of intuba-
tion and measured MMP-8 and MMP-9 levels at 48 hours of
ARDS, we stratified ARDS subjects into quartiles based on
number of ventilator days (Table 3). The mean duration of
mechanical ventilation in the top quartile was 21.9 days, strikingly
longer than the bottom 3 quartiles (10.560.6, 7.760.4 and
4.860.2, respectively, p,0.001). Endogenously active MMP-9
concentrations measured at 48 hours of ARDS were highest in
patients who went on to have the longest duration of mechanical
ventilation (67.5612 ng/mg vs. 7.461.2 ng/mg in those with the
fewest ventilator days, p,0.001; Table 3). Total MMP-9
concentration was not significantly different across the 4 quartiles.
When examined by ratio of active to total MMP-9, patients in the
top quartile of ventilator days had the highest active fraction
(53%69), in contrast to MMP-9 detected predominantly in the
latent form for patients in the 2
nd,3
rd and 4
th quartile of ventilator
days (active fraction ,15% across all three quartiles, p,0.001). In
contrast to MMP-9 measurements, the MMP-8 levels trended
towards a continuous increase across the quartiles of increasing
duration of ventilatory support (p=0.08). Measured TIMP-1,
MMP-9:TIMP-1 ratios, MPO and HNE concentrations showed
no clear relationships with duration of mechanical support.
Rising levels of active MMP-9 are seen in protracted
ARDS
Due to consistent covariate analysis demonstrating a significant
relationship between MMP-9 activity and the length of mechan-
ical ventilation, we analysed MMP-9 activity profile with ARDS
progression. Of the 33 ARDS subjects, 25 went on to require more
than five days of mechanical ventilation and continued to meet the
diagnostic criteria for ARDS. In this group of patients, a second
sample was obtained between 5–10 days of intubation (mean
6SEM=7.160.3 days, median=6 days). The concentrations of
active MMP-9 in these second samples were nearly 6-fold higher
than at 48 hours (Figure 2A; p=0.005). Unlike the first sample
obtained 48 hours after intubation, most of the MMP-9 measured
in the 2
nd sample was active (80% vs. 14%, respectively; p=0.005;
Figure 2A). Total MMP-8 levels in ARDS patients demonstrated a
very different pattern over time with a two-fold reduction seen at
day 6 (p=0.05; Figure 2B). Parallel studies performed in non-
ARDS controls who were intubated for greater than 5 days (n=5;
mean6SEM=760.7 days) demonstrated minimal changes in
MMP-8 and MMP-9 activity with time on the ventilator. In
contrast to ARDS subjects, less than 1% of MMP-9 was found in
the active fraction in these control samples collected between days
5-10 of intubation (vs. 80% in ARDS).
Reduction of excessive MMP-8 and MMP-9 in ARDS
tracheal aspirates by MMP inhibitors
To determine if small molecule inhibitors of MMPs could
normalize MMP-8 and MMP-9 activity in pediatric ARDS
tracheal aspirates, samples from subjects with high MMP-8 and
MMP-9 activity (n=4) were treated with specific and nonspecific
MMP inhibitors, and MMP activity was measured. MMP-8
activity was reduced by approximately 40% with EDTA and a
specific MMP-8 inhibitor (Figure 3A; p=0.04). Measurement of
MMP-9 activity demonstrated an approximate 60–100% reduc-
tion in activity by EDTA and a specific MMP-9 inhibitor
(Figure 3B; p=0.008) relative to vehicle control. Treatment of
ARDS samples with doxycycline, an antimicrobial agent with
MMP inhibitory properties [12] resulted in a 50% reduction in
MMP-9 activity (Figure 3B, p=0.04). A less dramatic inhibition
was seen with MMP-8, with only <10% reduction in activity
produced by doxycycline (Figure 3A; p=0.05).
Discussion
ARDS is a syndrome of severe pulmonary dysfunction and
refractory hypoxemia that results from a massive neutrophilic
inflammatory response [13]. Previous reports have implicated
Table 3. Examination of 48 hour inflammatory markers in ARDS subjects, segregated into quartiles for length of intubation.
1st Quartile
(n=8)
2nd Quartile
(n=8)
3rd Quartile
(n=8)
4th Quartile
(n=9) Overall p-value
Duration of intubation (Days) 21.962.9
a 10.560.6
b 7.760.4
b,c 4.860.2
c,d ,0.001
Active MMP-9 (ng/mg) 67.5612.1
a 9.762.5
b 7.161.7
b 7.461.2
b ,0.001
Total MMP-9
(ng/mg)
176668 190655 278682 80617 0.31
*Fraction of
Active MMP-9
52.868.7
a 14.567.3
b 5.561.6
b 11.562.0
b ,0.001
TIMP-1 (ng/mg) 116633 106632 136632 89627 0.64
MMP-9:TIMP-1 ratios 3.361.4 3.962.0 2.360.6 1.460.3 0.79
Total MMP-8 (ng/mg) 15956505 12276476 7296261 281682 0.087
HNE (ng/mg) 15.769.2 22.5612.3 7.162.9 5.362.0 0.72
MPO (ng/mg) 1156263646 1163865581 757661672 648161215 0.62
*Active MMP-9/Total MMP-9 in %.
Data are presented as means 6 SEM. Means in a row with different superscript letters are significantly different, p,0.05. Only active MMP-9 and fraction of active MMP-
9/total MMP-9 demonstrated positive correlation with length of intubation (p,0.001), while total MMP-8 demonstrated a trend towards correlation with length of
intubation.
doi:10.1371/journal.pone.0022596.t003
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lung inflammation [14–18], and support the hypothesis that
MMP-8 and -9 play key roles in neutrophil-mediated inflamma-
tion, which is central to the pathogenesis of ARDS.
In this study, we examined MMP-8 and MMP-9 levels in
pediatric ARDS, exploring relationships between their concentra-
tions, activity and modulation with disease progression. These two
MMPs were chosen based on our previous work in which
comprehensive MMP screening demonstrated that MMP-8 and 9
were among a limited number of MMPs found to be elevated in
pediatric ALI [7]. In this study, we identified significant increases
of active MMP-9 in a series of 33 children with ARDS compared
Figure 2. MMP-9 and MMP-8 levels in protracted ARDS. A: Increase in active MMP-9 with ARDS progression. Total MMP-9 remained elevated in
ARDS patients intubated for .5 days (n=25). With ARDS progression, approximately 80% of MMP-9 was found in the active form (prior to APMA
stimulation). Active MMP-9 at Day 6 of ARDS was 6-fold higher than at 48 hours of disease (mean6SEM 176661 ng/mg vs. 30616 ng/mg at 48 hrs,
respectively; *p=0.005). B: Decline in MMP-8 levels with ARDS progression. Total MMP-8 decreased with ARDS progression in those who remained
intubated for .5 days (n=25, mean6SEM 12456343 ng/mg at 48 hrs vs. 5376122 ng/mg at day 6, respectively; *p,0.05).
doi:10.1371/journal.pone.0022596.g002
Figure 3. Treatment of ARDS tracheal aspirates with MMP-8 and MMP-9 inhibitors. A. Tracheal aspirates from ARDS subjects (n=4) with
high MMP-8 activity were examined in the presence of different MMP inhibitors. MMP-8 was reduced by 40–50% relative to basal activity when
incubated with 5 mM of EDTA (
{p=0.04) and 30 ng/ml of a specific MMP-8 inhibitor (
{p=0.04) versus basal activity and vehicle controls. Incubation
with 100 mcg/ml of doxycycline resulted in a 10% decrease in MMP-8 activity compared to basal levels (*p=0.05). B. Tracheal aspirates from ARDS
subjects (n=4) with high MMP-9 activity were examined in the presence of different MMP inhibitors. MMP-9 activity decreased by 70–100% relative
to basal activity in the presence of EDTA (5 mM;
{p=0.008) and a MMP-9 specific inhibitor (50 ng/ml;
{p=0.008). Inhibition with doxycycline
(100 mcg/ml) decreased MMP-9 activity by approximately 40% of basal activity (*p=0.04).
doi:10.1371/journal.pone.0022596.g003
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independent of age, gender, disease etiology and severity. In
addition, the active fraction of MMP-9 further increased with
ARDS progression. These findings point towards dysregulation of
MMP-9 in ARDS, with depressed TIMP-1 levels contributing only
in part to this effect. In control subjects, no significant changes
were seen in MMP-8 and MMP-9 over time while subjects
remained on the ventilator. Furthermore, almost all of the MMP-9
detected was inactive in our ventilator-control group, indicating
the presence of normal MMP-9 regulation (not shown).
In the current report, both MMP-8 and -9 had positive
correlations with MPO and HNE, enzymes present in abundance
in neutrophil granules, suggesting that neutrophils were an
important source of the MMPs. In comparison to MMP-8,
MMP-9 had a weaker correlation with MPO and HNE. Since
more than one-third of our ARDS subjects had viral induced
ARDS, epithelia derived MMP-9 {described in respiratory viral
infections [19]} may potentially have contributed to high MMP-9
levels, in addition to MMP-9 released from activated neutrophils.
To date, there have been contradictory reports regarding
whether MMP-9 is protective or harmful in lung injury models
[20–23]. In the current study, subjects who went on to require
longer ARDS-related ventilator support and had fewer ventilator-
free days demonstrated higher active MMP-9, fraction of active
MMP-9 and total MMP-8 levels at 48 hours of ARDS,
independent of age, gender, oxygenation defect, disease etiology
and severity of illness. This observation suggests that up-regulation
of these MMPs early in disease predicted a more protracted ARDS
course. This was seen most dramatically in patients with very
prolonged ventilator support (Table 3), who had extremely high
levels of active MMP-9. The findings support the hypothesis that
active MMP-9 may serve as a biomarker to predict the length of
ventilator support in the pediatric ARDS population. The
relationships between MMP levels and other clinical parameters
such as PaO2/FiO2 ratios, OI, PRISM scores and MOSF were
less clear than their relationships with duration of ventilator
support. While we observed no correlation between MMP levels
and ARDS related mortality, firm conclusions cannot be drawn as
only one ARDS subject died from ARDS related complications. In
this one ARDS subject, MMP-9 activity and MMP-9:TIMP-1
ratio remained elevated throughout his disease course.
Elevated MMP-8 and MMP -9 activity in ARDS lung secretions
could be reduced by treatment with MMP inhibitory molecules ex
vivo (Figure 3). Tetracycline derivatives have been demonstrated
to be potent MMP inhibitors [12,24]. In a study by Kim JH et al,
MMP-9 inhibition by pre-treatment with a chemically modified
tetracycline derivative decreased the degree of ventilator induced
lung injury in rats exposed to high volume ventilation [20]. Other
studies using acute animal models of lung injury such as after
cardiopulmonary bypass [21] and after infusion of Escherichia coli
lipopolysaccharide [25] also demonstrated that blocking of
proteases, primarily MMP-9 and neutrophil elastase with a
modified tetracycline (COL-3) prevented lung injury and ulti-
mately the development of ARDS. COL-3 also completely
prevented all the pathological lung changes seen in a porcine
model of sepsis induced ARDS [26]. In our study, EDTA, MMP
specific inhibitors and doxycyline inhibited MMP-9 and to a lesser
extent MMP-8 activity, suggesting that strategies utilizing small
molecule agents to restore MMP regulation may retain activity in
the ARDS environment. These findings provide support for
further studies examining cause-effect relationships between MMP
activity and the pathogenesis of ARDS.
Patients who were on steroids or immunosuppressive medica-
tions prior to intubation (both for control and ARDS subjects)
were excluded from the study secondary to the potential effect of
these medications on MMP expression and activity. However, out
of the 33 enrolled ARDS subjects, three received hydrocortisone
(100 mg/m
2/day) for shock and five received solumedrol (2 mg/
kg/day) for wheezing within the first two days of intubation. No
correlation was found between the use of steroids and MMP
expression or with markers of disease severity and outcome
measures. None of the control subjects received steroids during the
course of their intubation. However, due to the small number of
patients who received steroids in our cohort, firm conclusions
cannot be drawn.
One limitation of this study is that it was performed in one
tertiary pediatric medical institution only. Future examination of
MMP-8 and -9 as biomarkers of pediatric ARDS would benefit
from a larger multicenter approach. Although this study
demonstrated up-regulation of active MMP-9 in pediatric ARDS
subjects and association between increased MMP-8 and MMP-9
early in disease course with duration of mechanical ventilation, it is
crucial to recognize that examination of MMP-8/9 levels with
other previously recognized ARDS biomarkers such as plasma von
Willebrand factor antigen, plasminogen activator inhibitor-1 and
B-type natriuretic peptide [27–29] may provide greater prognostic
value than MMP biomarkers alone. Finally, although we
demonstrate robust blockade of MMP-8/9 activity in tracheal
aspirates from ARDS subjects, it is unknown whether in-vivo
blockade of these proteases may alter the disease course and
outcome. However, this study provides the foundation to support
potential therapeutic trials examining specific agents with MMP
inhibitory activities (such as doxycyline) as modulators of excessive
MMP-8 and/or MMP-9 activity in children with ARDS.
Conclusion
The results of this study confirm our previous reports that
MMP-8 and -9 are increased in pediatric ARDS, and provide
evidence that early elevation of MMP-8 and MMP-9 levels,
particularly active MMP-9 predicts the duration of mechanical
ventilation. This relationship is independent of age, gender,
disease etiology and disease severity. These findings support a role
of protease dysregulation in the pathogenesis of pediatric ARDS,
and suggest that elevated MMP-8 and/or active MMP-9 may
have a prognostic value in pediatric ARDS patients. Larger
prospective studies are warranted to confirm these findings with a
goal of determining whether MMP-8/9 are appropriate targets to
modify patient outcomes.
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